肝硬変治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Liver Cirrhosis Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Etiology
• Symptoms
• Pathophysiology
• Diagnosis
• Epidemiology
• Prevention
• Treatment
• Impact of alcohol consumption on liver cirrhosis

PART 06: Pipeline portfolio
• Information on pipeline candidates
• Clinical trials for liver cirrhosis

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type of molecule
• Biologics
• Small molecules

PART 09: Market segmentation by types of liver cirrhosis

PART 10: Market segmentation by types of liver cirrhosis treatment
• Medications to treat causes of liver cirrhosis
• Medications to treat complications of liver cirrhosis

PART 11: Geographical segmentation
• Liver cirrhosis medication market in Americas
• Market overview
• Market size and forecast
• Liver cirrhosis medication market in EMEA
• Market overview
• Market size and forecast
• Liver cirrhosis medication market in APAC
• Market overview
• Market size and forecast

PART 12: Market drivers
• High prevalence of liver cirrhosis
• Advances in technology
• High unmet medical needs
• Changes in lifestyle

PART 13: Impact of drivers

PART 14: Market challenges
• Use of alternative therapies
• Adverse effects of drugs
• Poor patient adherence
• Stringent regulatory guidelines

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Rise in public awareness
• Increase in R&D
• Use of off-label drugs
• Patient assistance programs

PART 17: Vendor landscape
• Competitive scenario
• F Hoffmann-La Roche
• GlaxoSmithKline
• Gilead Sciences
• Johnson & Johnson
• Merck
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Stages of liver diseases
Exhibit 03: Causes of liver cirrhosis
Exhibit 04: Diagnosis of liver cirrhosis
Exhibit 05: Effect of alcohol consumption on liver cirrhosis
Exhibit 06: Pipeline molecules for liver cirrhosis
Exhibit 07: Clinical trials by development phase
Exhibit 08: Clinical trials by trial status
Exhibit 09: Global liver cirrhosis medication market 2015-2020 ($ billions)
Exhibit 10: Five forces analysis
Exhibit 11: Four main types of liver cirrhosis
Exhibit 12: Market share by types of liver cirrhosis
Exhibit 13: Types of treatment for liver cirrhosis
Exhibit 14: Global liver cirrhosis medication market segment by geography 2015
Exhibit 15: Global liver cirrhosis medication market segment by geography 2015-2020 ($ millions)
Exhibit 16: Liver cirrhosis medication market in Americas ($ millions)
Exhibit 17: Liver cirrhosis medication market in EMEA ($ millions)
Exhibit 18: Liver cirrhosis medication market in APAC ($ billions)
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 22: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 24: F Hoffmann-La Roche: YoY growth and revenue of Pegasys 2012-2014 ($ billions)
Exhibit 25: F Hoffmann-La Roche: Key takeaways
Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 27: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 28: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 29: GlaxoSmithKline: YoY growth and revenue of Epivir 2012-2014 ($ millions)
Exhibit 30: Gilead Sciences: Geographical segmentation by revenue 2014
Exhibit 31: Gilead Sciences: YoY revenue comparison of Sovaldi 2013-2014 ($ millions)
Exhibit 32: Gilead Sciences: YoY growth and revenue of Viread 2012-2014 ($ millions)
Exhibit 33: Gilead Sciences: Key takeaways
Exhibit 34: Johnson & Johnson: Business segmentation by revenue 2014
Exhibit 35: Johnson & Johnson: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 36: Johnson & Johnson: Geographical segmentation by revenue 2014
Exhibit 37: Johnson & Johnson: YoY growth and revenue of Incivo 2012-2014 ($ millions)
Exhibit 38: Johnson & Johnson: YoY revenue growth of Olysio 2012-2014 ($ millions)
Exhibit 39: Johnson & Johnson: Key takeaways
Exhibit 40: Merck: Business segmentation by revenue 2014
Exhibit 41: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 42: Merck: Geographical segmentation by revenue 2014
Exhibit 43: Merck: YoY growth and revenue of PegIntron 2012-2014 ($ millions)
Exhibit 44: Merck: YoY growth and revenue of Victrelis 2012-2014 ($ millions)
Exhibit 45: Merck: Key takeaways


【レポート販売概要】

■ タイトル:肝硬変治療薬の世界市場2016-2020
■ 英文:Global Liver Cirrhosis Market 2016-2020
■ 発行日:2016年5月6日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8209
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。